PI3K/Akt/CREB activator 1

• CAT Number: I042611
• CAS Number: 2708177-73-3
• Molecular Formula: C19H15F4NO3
• Molecular Weight: 381.32
• Purity: ≥95%
• Synonyms: (2S)-3-(4-fluorophenyl)-2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]propanoic acid
• InChI: InChI=1S/C19H15F4NO3/c20-15-8-3-13(4-9-15)11-16(18(26)27)24-17(25)10-5-12-1-6-14(7-2-12)19(21,22)23/h1-10,16H,11H2,(H,24,25)(H,26,27)/b10-5+/t16-/m0/s1
• InChIKey: VXTNIOWCDILANK-YKXBDCQTSA-N
• SMILES: C1=CC(=CC=C1CC(C(=O)O)NC(=O)C=CC2=CC=C(C=C2)C(F)(F)F)F

PI3K/Akt/CREB activator 1 (compound AE-18) is a potent, orally active PI3K/Akt/CREB activator. PI3K/Akt/CREB activator 1 promotes neuronal proliferation, induced differentiation of Neuro-2a cells into a neuron-like morphology, and accelerated the establishment of axon-dendrite polarization of primary hippocampal neurons through upregulating brain-derived neurotrophic factor via the PI3K/Akt/CREB pathway. PI3K/Akt/CREB activator 1 can be used in research of vascular dementia (VaD)[1].
PI3K/Akt/CREB activator 1 (compound AE-18; 10 and 20 μM; 48 h) induces neurite outgrowth and proliferation through upregulating BDNF via the PI3K/Akt/CREB pathway Neuro-2a cells[1].
PI3K/Akt/CREB activator 1 (10 and 20 μM; neurons) enhances neuronal differentiation and axon-dendrite polarization in cultured hippocampal neurons through the PI3K/AKT signal pathway[1].
PI3K/Akt/CREB activator 1 (compound AE-18; 5 and 10 mg/kg; i.g.; male Sprague-Dawley rats with chronic cerebral hypoperfusion (CCH) model) improves cerebral blood flow (CBF) recovery after bilateral common carotid artery occlusion (BCCAO)[1].
PI3K/Akt/CREB activator 1 (5 and 10 mg/kg; i.g.; for 5 d) mitigates impairment of learning and memory in chronic cerebral hypoperfusion (CCH) rat model and alleviates CCH-induced pathological injury in the hippocampus after BCCAO[1].

Reference

[1]. Feng JH, et, al. Protective Effects of 4-Trifluoromethyl-(E)-cinnamoyl]-L-4-F-phenylalanine Acid against Chronic Cerebral Hypoperfusion Injury through Promoting Brain-Derived Neurotrophic Factor-Mediated Neurogenesis. ACS Chem Neurosci. 2022 Oct 16.
 [Content Brief]